Journal of the Neurological Sciences
Volume 201, Issue 1 , Pages 1-7 , 15 September 2002

Deteriorating ischaemic stroke: cytokines, soluble cytokine receptors, ferritin, systemic blood pressure, body temperature, blood glucose, diabetes, stroke severity, and CT infarction-volume as predictors of deteriorating ischaemic stroke

  • Hanne Christensen

      Affiliations

    • Department of Neurology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
    • ,
  • Gudrun Boysen

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +45-35-31-24-54; fax: +45-35-31-25-95
    • Department of Neurology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
    • ,
  • Helle Hjorth Johannesen

      Affiliations

    • Department of Radiology, Bispebjerg Hospital, Copenhagen, Denmark
    • ,
  • Erik Christensen

      Affiliations

    • Department of Internal Medicine, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
    • ,
  • Klaus Bendtzen

      Affiliations

    • Institute for Inflammatory Research, Rigshospitalet University Hospital, Copenhagen, Denmark

Received 14 March 2002 ,Revised 6 May 2002 ,Accepted 15 May 2002.

References 

  1. Toni D, Fiorelli M, Gentile M, Basianello S, Argentino C, Pozzili C, et al.  Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis and prognosis. Arch. Neurol. 1995;52:670–675
  2. Britton M, Roden A. Progression of stroke after arrival at hospital. Stroke. 1985;16:629–632
  3. Miller Fisher C. The use of anticoagulants in cerebral thrombosis. Neurology. 1958;8:311–322
  4. Bath PMW, Lindenstrøm E, Boysen G, De Deyn P, Friis P, Leys D, et al.  Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. Lancet. 2001;358:702–710
  5. Rödén-Jüllig Å, Britton M. Effectiveness of heparin treatment for progressing ischaemic stroke: before and after study. J. Intern. Med. 2000;248:287–291
  6. Dávalos A, Cendra E, Teruel J, Martinez M, Genis D. Deteriorating ischemic stroke: risk factors and prognosis. Neurology. 1990;40:1865–1869
  7. Jørgensen HS, Nakayama H, Raaschou HO, Olsen TS. Effects of blood pressure and diabetes on stroke in progression. Lancet. 1994;344:156–159
  8. Castillo J, Dávalos A, Noya M. Progression of ischemic stroke and excitotoxic aminoacids. Lancet. 1997;349(79):83
  9. Castillo J, Rama R, Dávalos A. Nitric oxide-related brain damage in acute ischemic stroke. Stroke. 2000;31:852–857
  10. Vila N, Castillo J, Dávalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2000;31:2325–2329
  11. Dávalos A, Castillo J, Murrugat J, Fernandez-Real JM, Armengou A, Cacabelos P, et al.  Body iron stores and early neurologic deterioration in acute cerebral infarction. Neurology. 2000;54:1568–1574
  12. DeGraba T, Hallenbech JM, Pettigrew KD, Dutka AJ, Kelly BJ. Progression in acute stroke. Stroke. 1999;30:1208–1212
  13. Dávalos A, Toni D, Iweins F, Lesaffre E, Bastianello S, Castillo J, et al.  Neurological deterioration in acute ischemic stroke. Potential predictors and associated factors in the European Cooperative Acute Stroke Study (ECASS). Stroke. 1999;30:2631–2636
  14. Lindenstrøm E, Boysen G, Christiansen LW, à Rogvi Hansen B, Nielsen PW. Reliability of Scandinavian Neurological Stroke Scale. Cerebrovasc. Dis. 1991;1:103–107
  15. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–607
  16. van der Worp HB, Claus SP, Bär PR, Ramos LMP, Algra A, van Gijn J, et al.  Reproduceability of measurements of cerebral infarct volume on CT Scans. Stroke. 2001;32:424–428
  17. Svenson M, Hansen MB, Heegaard P, Abell K, Bendtzen K. Specific binding of interleukin 1 (IL-1)α and IL-receptor antagonist (IL-1ra) to human serum. High-affinity binding of IL-1ra to soluble IL-1 receptor type I. Cytokine. 1993;5:427–435
  18. Christensen H, Boysen G, Christensen E, Johannesen HH, Bendtzen K. Plasma cytokines in acute stroke. J Stroke Cerebrovasc Dis, in press.
  19. Telle DS. Salt and blood pressure revisited. BMJ. 1996;312:1240–1241
  20. Miller Fisher C. Anticoagulant therapy in cerebral thrombosis and cerebral embolism. Neurology. 1961;11:119–131
  21. Carter AB. Anticoagulant treatment in progressing stroke. BMJ. 1961;70–73
  22. Baker RN, Broward JA, Fang HC, Miller Fisher C, Groch SN, Heyman A, et al.  Anticoagulant therapy in cerebral infarction. Report on a cooperative study. Neurology. 1962;12:823–835
  23. Royden Jones H, Millikan CH. Temporal profile (clinical course) of acute carotid system cerebral infarction. Stroke. 1976;7:64–71
  24. Royden Jones H, Millikan CH, Sandok BA. Temporal profile (clinical course) of acute vertebrobasilar system infarction. Stroke. 1980;11:173–177
  25. Patrick BK, Ramirez-Lassepas M, Snyder BD. Temporal profile of vertebrobasilar territory infarction. Prognostic implications. Stroke. 1980;11:643–648
  26. Lodder J, Gorsselink EL. Progressive stroke caused by CT-verified small deep infarcts: relation with the size of the infarct and clinical outcome. Acta Neurol. Scand. 1985;71:328–330
  27. Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke in acute partial stroke. Ann. Intern. Med. 1986;105:825–828
  28. Tei H, Uchiyama S, Ohara K, Kobayashi M, Uchiyama Y, Fukuzawa M. Deteriorating ischemic stroke in 4 clinical categories classified by the Oxfordshire Community Stroke Project. Stroke. 2000;31:2049–2054

PII: S0022-510X(02)00160-0

Journal of the Neurological Sciences
Volume 201, Issue 1 , Pages 1-7 , 15 September 2002

Article Tools